Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Reprogram ; 24(5): 259-270, 2022 10.
Article in English | MEDLINE | ID: mdl-36137065

ABSTRACT

In the last decade, direct reprogramming has emerged as a novel strategy to obtain mature and functional dopamine neurons from somatic cells. This approach could overcome issues linked to the use of human pluripotent stem cells such as ethical concerns and safety problems that can arise from the overgrowth of undifferentiated cells after transplantation. Several conversion methodologies have been developed to obtain induced DA neurons (iDANs) or induced DA neuron progenitors (iDPs). iDANs have also proved to successfully integrate in mice striatum, alleviating Parkinson's disease (PD) motor symptoms. In the next decade, human iDANs and/or iDPs could be translated to clinic to achieve a patient-tailored therapy, but current critical issues hinder this goal, such as the low conversion rate of adult human fibroblasts and the risks associated with lentiviral delivery of conversion factors. In this study, we summarize the strategies and recent improvements developed for the generation of mouse and human iDANs/iDPs. Furthermore, we discuss the more recent application of in vivo direct conversion, which may enable clinical therapies for PD by means of brain in situ delivery of dopaminergic reprogramming transcription factors.


Subject(s)
Parkinson Disease , Pluripotent Stem Cells , Adult , Cell Differentiation/physiology , Dopaminergic Neurons , Humans , Parkinson Disease/therapy , Transcription Factors
2.
Biomolecules ; 10(9)2020 09 03.
Article in English | MEDLINE | ID: mdl-32899172

ABSTRACT

Midbrain dopamine neurons have crucial functions in motor and emotional control and their degeneration leads to several neurological dysfunctions such as Parkinson's disease, addiction, depression, schizophrenia, and others. Despite advances in the understanding of specific altered proteins and coding genes, little is known about cumulative changes in the transcriptional landscape of noncoding genes in midbrain dopamine neurons. Noncoding RNAs-specifically microRNAs and long noncoding RNAs-are emerging as crucial post-transcriptional regulators of gene expression in the brain. The identification of noncoding RNA networks underlying all stages of dopamine neuron development and plasticity is an essential step to deeply understand their physiological role and also their involvement in the etiology of dopaminergic diseases. Here, we provide an update about noncoding RNAs involved in dopaminergic development and metabolism, and the related evidence of these biomolecules for applications in potential treatments for dopaminergic neurodegeneration.


Subject(s)
Dopaminergic Neurons/chemistry , Dopaminergic Neurons/metabolism , Mesencephalon/chemistry , Mesencephalon/metabolism , Parkinson Disease/drug therapy , RNA, Untranslated/physiology , RNA, Untranslated/therapeutic use , Animals , Dopamine/metabolism , Dopaminergic Neurons/physiology , Gene Expression Regulation , Humans , Parkinson Disease/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...